KRAS and pancreatic neoplasm: Conversely, in KRAS-mut contexts (MiaPaCa2 pancreatic cancer; A549 and A-427 NSCLC), EGFR family activation was dispensable for dabrafenib-induced paradoxical ERK activation, as the addition of lapatinib to dabrafenib had no appreciable effect on ERK activation (Fig. 7e).